Immutep Limited IMMP
3.26 USD -0.14 (-4.12%)
Regular-session close
3.25 -0.01 -0.31%
Pre-market · Nov 18, 5:25 AM ET
3.16 Day range 3.38
2.66 52-week range 70.60
- YTD
- +13.99%
- 1 year
- +76.22%
Benzinga news
benzinga.com Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.benzinga.com Immutep Reports Encouraging EFTISARC-NEO Phase II Sarcoma Survival Data; Efti + KEYTRUDA + Radiotherapy Shows 81.1% 12-Month DFS, 94.1% LRFS And 86.2% DMFS In 38 Patients First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).With a median…
benzinga.com Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027 Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials…
benzinga.com Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash…
benzinga.com Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced health-related quality of life
